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Abstract
CD4+ T helper memory (Thmem) cells influence both natural and vaccine-boosted immunity,
but mechanisms for their maintenance remain unclear. Pro-survival signals from the com-
mon gamma-chain cytokines, in particular IL-7, appear important. Previously we showed in
healthy volunteers that a booster vaccination with tetanus toxoid (TT) expanded peripheral
blood TT-specific Thmem cells as expected, but was accompanied by parallel increase of
Thmem cells specific for two unrelated and non cross-reactive common recall antigens.
Here, in a new cohort of healthy human subjects, we compare blood vaccine-specific and
bystander Thmem cells in terms of differentiation stage, function, activation and proliferative
status. Both responses peaked 1 week post-vaccination. Vaccine-specific cytokine-produc-
ing Thmem cells were predominantly effector memory, whereas bystander cells were mainly
of central memory phenotype. Importantly, TT-specific Thmem cells were activated
(CD38High HLA-DR+), cycling or recently divided (Ki-67+), and apparently vulnerable to
death (IL-7RαLow and Bcl-2 Low). In contrast, bystander Thmem cells were resting (CD38
Low
HLA-DR- Ki-67-) with high expression of IL-7Rα and Bcl-2. These findings allow a clear dis-
tinction between vaccine-specific and bystander Thmem cells, suggesting the latter do not
derive from recent proliferation but from cells mobilized from as yet undefined reservoirs.
Furthermore, they reveal the interdependent dynamics of specific and bystander T-cell
responses which will inform assessments of responses to vaccines.
Introduction
CD4+ T helper (Th) cells play crucial roles in both natural and vaccine-induced immunity.
Upon priming, naïve cells differentiate into distinct functional subsets with defined phenotypic
and homing properties including Th1, Th2, Th17, T follicular helper, or induced T regulatory
cells. Each subset appears to be tailored to exert pathogen-specific protection or immune
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regulation [1] [2]. Once antigen has been cleared, central memory (TCM) and effector memory
(TEM) T cells remain to provide immune surveillance in lymphoid and peripheral non-lym-
phoid tissues respectively [3].
It is evident from human studies that natural or vaccine-induced Thmem cells can persist for
very long periods [4–6] but the mechanisms responsible for their maintenance remain unclear.
However, pro-survival signals from the common gamma chain (γc) cytokines, in particular IL-
7, appear to be important [7]. IL-7 receptor signalling and expression of anti-apoptotic mole-
cules, such as Bcl-2, promote cell survival during the T cell contraction phase and can contrib-
ute to successful effector-to-memory transition [8]. Studies in mice suggest that this transition
may occur in the bone marrow, where antigen-specific CD4+ T cells relocate after being acti-
vated in secondary lymphoid organs. There, they down-regulate gene expression and prolifera-
tion, and survive as highly reactive memory cells in proximity to IL-7-expressing stromal cells
that provide survival niches [9,10]. In humans, polyfunctional CD4+ memory T cells accumu-
late in the bone marrow in close proximity to IL-15 producing cells [11].
Previously, we investigated the dynamics of Thmem cell responses to TT booster vaccination
in healthy volunteers. Surprisingly, the expected expansion of TT-specific Thmem cells was
accompanied by an increase of Thmem cells specific for two unrelated and non-cross reactive
common recall antigens: purified protein derivative from tuberculin (PPD) and Candida albi-
cans (C. Alb) [12]. These bystander responses had parallel kinetics to the specific response. We
hypothesized that the increase of vaccine non-specific Thmem cells could result from TCR-inde-
pendent activation, most likely cytokine-mediated, occurring in a shared microenvironment
during the vaccine-specific secondary immune response. Indeed, recent findings suggest that
the cytokines produced in reactive lymph nodes can diffuse throughout the node and influence
bystander cells not in close proximity to the cytokine source [13]. We demonstrated in a
mouse model, that a recall response to TT can induce proliferation of previously activated
CD4+ T cells specific for the unrelated antigen ovalbumin, proliferation being proportional to
the strength of the immune responses and likely to be IL-2 mediated [14]. Another γc cytokine,
IL-15, has also been shown to mediate the bystander activation and proliferation of CD8+
memory-phenotype T cells observed in mice, following viral infections or treatment with
virus-mimetics or bacterial products [15,16].
In terms of functional outcome, it is still debated whether in vivo bystander activation
(cytokine-mediated) of memory T cells would promote survival or lead to increased cell death.
In one study, human CD4+ memory T cells activated in vitro in a bystander fashion displayed
a gene expression profile distinct from antigen-specific T cells [17]. While the in vitro-acti-
vated bystander T cells up-regulated pro-apoptotic genes, transcripts of the pro-survival NF-
kB signaling pathway were also up-regulated, making predictions of survival in vivo difficult.
In mice, relative stability of CD4+ memory T cells specific for lymphocytic choriomeningitis
virus has been observed following multiple heterologous virus infections, despite the parallel
loss of lymphocytic choriomeningitis virus-specific CD8+ memory T cells [18]. Furthermore,
vaccinia virus infection promoted enhanced survival of super antigen-activated T cells [19].
While conclusions on the fate of memory CD4+ T cells remain unclear, promotion of survival
via bystander effects would be more consistent with maintenance of long-term CD4+ T-cell
memory.
Here, we have used tetanus toxoid recall vaccination of healthy human subjects as an oppor-
tunity to probe the nature of vaccine-specific and vaccine-stimulated bystander Thmem.
We focused first on their differentiation stage and migratory properties, by defining their
belonging to the TCM and TEM subsets of memory T cells [3]. Then, we addressed their survival
potential, by analysing expression of IL-7Rα (CD127) which confers cells the ability to respond
to the homeostatic cytokine IL-7 [8], and the levels of the anti-apoptotic molecule Bcl-2 [20].
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Finally, we studied their activation status and in vivo proliferative activity by evaluating the
proportion of CD38 and HLA-DR, and Ki-67 positive cells, respectively [21].
Our findings reveal key differences between vaccine-specific and bystander Thmem cells,
both increased in number in the peripheral blood following vaccination, and both sharing simi-
lar response kinetics. Whilst vaccine-specific Thmem cells displayed typical features of recently
generated and potentially short-lived effectors, which were still highly activated and had
recently divided or were still doing so, bystander cells appeared to derive from a central mem-
ory compartment of relatively quiescent and non-proliferating cells with preserved survival
potential.
Materials and Methods
Ethics statement
Ethical approval for the study was obtained from the Institutional Review Board and the South-
ampton & S.W. Hants Joint Research Ethics Committee (submission number 242/99). All sub-
jects gave written informed consent for study participation in accordance with the Declaration
of Helsinki.
Vaccination and sample collection
Six healthy adults (3 males, 3 females, median age 32, range 25–47) received a single dose of TT
vaccine (Adsorbed Tetanus Vaccine BP, Aventis Pasteur MSD) administered intramuscularly.
All subjects had already been vaccinated with TT and conventional Bacillus Calmette–Guérin,
but they had not received booster injections in the previous five years. Sample collection and
storage was done according to our previously published protocol [12], with the exception that
an additional blood sample was taken one week after vaccination in all the subjects.
Antigens
TT not absorbed (code 02/232) and C. Alb whole extract cytoplasmic protein were purchased
from the National Institute for Biological Standards and Control, NIBSC, UK. PPD prepared
from human strains ofMycobacterium tuberculosis was obtained from Evans Vaccines Limited,
UK.
Antibody panels
The following anti-human mAbs were used: CD3 APC-Cy7 (HIT3a), CD4 Pacific Blue
(OKT4), CD38 APC (HIT2), CD45RA Brilliant Violet 421 (Hl100), CD127 Brilliant Violet 421
(A019D5), CD197 (CCR7) Alexa Fluor 647 (G043H7), HLA-DR PE-Cy7 (L243) and IL-2
FITC (MQ1-17H12) purchased from BioLegend; CD4 V500 (RPA-T4), CD8 V500 (RPA-T8),
Bcl-2 FITC (Bcl-2/100) and Ki-67 FITC (B56) purchased from BD Biosciences; IFN-γ PE-Cy7
(4S.B3) obtained from eBioscience and CD40L PE (TRAP 1) obtained from Beckman Coulter.
Analysis of viable, apoptotic and necrotic cells by annexin V/propidium
iodide (AV/PI) staining
To exclude the possibility of the fluctuations in T-cell responses being the result of variations
in cell viability, the percentages of apoptotic and necrotic cells were analysed in both lympho-
cytes (effectors) and monocytes (predominant antigen-presenting population) prior to cell cul-
ture, using AV/PI staining. Briefly, PBMNC were defrosted and counted; 2.5 x 105 cells were
washed and re-suspended in 300μl of AV binding buffer (Biolegend). AV FITC (in house,
1.25μg) and P.I. (Biolegend, 0.22μg) were added to each tube. Cells were left 10–15’ at room
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temperature and then analysed on a Canto II flow cytometer. AVnegPIneg cells were considered
viable. No significant changes were found between time points; the mean percentage and stan-
dard deviation of viable lymphocytes and monocytes calculated on all subjects and on all time
points were equal to 90.6% ± 4.55 and 95.2% ± 2, respectively.
IFN-γ ELISPOT
T cell responses to vaccination were screened and evaluated using a 40h IFN-γ ELISPOT assay
according to the method and criteria previously described [12]. Briefly, 2 x105 PBMNC were
cultured in triplicates, in RPMI-1640, L-glutamine, penicillin, streptomycin, sodium pyruvate,
and 5% human AB sera (Lonza) (complete medium), in the absence (negative control) or in
the presence of either TT (10μg/ml), PPD (10μg/ml), C. Alb (10μg/ml). Ag-specific responses
are reported here as the number of spots per 1x106 PBMNC in antigen-stimulated cultures
minus the number of spots in the corresponding negative control.
Intracellular CD40L and cytokine staining
For intracellular staining, 2 x 106 PBMNCs were re-suspended in 1ml of complete medium and
cultured in 15ml, 120x17mm, polypropylene tubes (SARSTEDT, Nümbrecht, Germany), in
the absence (control) or in the presence of either TT (10μg/ml), PPD (15μg/ml) or C. Alb
(10μg/ml). Anti-CD28 (clone CD28.2, eBioscience) was added to all tubes (1μg/ml). After 90
minutes, brefaldin A (Golgi Plug, BD Biosciences) was added (1/1000 dilution). After 6h, cells
were washed and stained for surface markers first, and then they were permeabilized and
stained for intracellular markers. Data were acquired on a Canto II flow cytometer and ana-
lyzed using FlowJo (7.6.5) (Treestar) software. For analysis of antigen-specific CD4+ T cells,
between 1.5–1.8 x 106 events in the singlet gate were acquired. Responses were considered posi-
tive if the frequency of the events in antigen-stimulated cultures was 0.01%, and the fre-
quency of background events was 30% of the frequency of events in the antigen-stimulated
cultures.
Statistical Analysis
Continuous data sets were tested for normal distribution and data analysed using the non-
parametric MannWhitney U Test or independent sample T-test utilising Holm-Sidak correc-
tion for multiple comparisons. Matched pairs were analysed using Paired student T-test. Paired
analysis across a time course was performed using Friedman’s test and Dunn’s multiple com-
parison test incorporating a multiplicity correction. Statistical analysis was performed using
SPSS v21.0 (SPSS Inc,. Chicago,Il.,US) and GraphPad Prism v6.0 (GraphPad Software Inc., San
Diego,Cl.,US).
Results
Parallel increase of vaccine-specific and bystander CD4+ memory T
cells following TT booster vaccination
We have previously shown how in 12 healthy volunteers a booster vaccination with TT induces
expansion of vaccine-specific (TT) and an increase of bystander (PPD and C. Alb) Thmem cells,
with parallel kinetics [12]. Importantly, no cross-reactivity was demonstrated between TT and
PPD or C.Alb. To further characterise and distinguish the vaccine-specific from the bystander
response, a new cohort of 5 healthy subjects already immune to TT, received a recall TT vacci-
nation. To confirm our previous findings, T cell responses were measured by an IFN-γ ELI-
SPOT. The duration of the assay was optimised to allow optimal detection of cytokine
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response to protein antigens without induction of proliferation. Results show expansions of
TT-specific T cells in all five subjects, with a peak at week 1 post-vaccination (Fig 1A). Parallel
increases of IFN-γ-secreting T cells in response to PPD were evident, with similar although
weaker responses against C. Alb (Fig 1A). Accordingly, pooled data demonstrated a
Fig 1. Kinetics of vaccine-specific and bystander T cell responses to TT recall vaccination. Five healthy subjects received a booster vaccination with
TT and T cell responses were measured by a 40h IFN-γ ELISPOT assay, and reported as the mean number of spots ± SD of triplicate antigen-stimulated
cultures, after subtracting the correspondent negative (no antigen) control. (A) Individual responses (1–5) and mean ± SD of the mean responses from all five
subjects. Vaccination (Wk 0) induces increase of both vaccine-specific (TT) and vaccine-unrelated (PPD, C. Alb) IFN-γ-producing cells. Responses are
highly dynamic and peak one week after vaccination. (B) Comparison between IFN-γ responses at baseline (Wk 0) and one week after vaccination (Wk 1).
Vaccination induces a statistically significant increase in the number of TT-specific and PPD-specific IFN-γ-producing cells. A paired t test was applied and a
two-tailed p value is shown.
doi:10.1371/journal.pone.0136717.g001
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significantly increased number of TT- and PPD-specific IFN-γ-producing cells at week 1 com-
pared to baseline (Fig 1B). A similar trend was seen for C. Alb-specific responses, although dif-
ferences failed to reach statistical significance, possibly because of the low level of detectable T-
cell memory (Fig 1B). Increases were followed by contractions in both vaccine-specific and
bystander responses, which then rose again in some individuals or remained stable in others.
These fluctuations were not due to differential cell viability between time points (see Materials
and methods) and were also seen when fresh PBMNC collected from an additional vaccinated
subject, were used (S1 Fig). They rather reveal the dynamic nature of the CD4+ memory T cell
response in humans who, in contrast to mice maintained in germ-free environment, are con-
stantly exposed to environmental antigens.
These results confirm our previous data [12] in a new cohort of healthy subjects and set the
scene for further analysis.
Antigen-specific cells were identified within the CD3+CD4+ population through assessment
of CD40L expression, after a short (6h) in vitro antigen re-stimulation. This method ensures
stability of phenotypic features and allows analysis of a broader population of antigen-specific
cells, compared to longer protocols based on cytokine production only [22–24]. Cells were
functionally characterized by evaluating cytokine (IFN-γ, IL-2) production. An example of the
gating strategy and data relative to the pre-vaccination and week 1 time points for subject 1,
are shown in Fig 2A; the response kinetics up to week 8 from the same individual are shown in
Fig 2B.
In the depicted subject, few TT-specific CD4+CD40L+ T cells were evident prior to vaccina-
tion, however they were clearly detected 1 week post-vaccination (0.138% after background sub-
traction); of these 37% produced IL-2 (0.052% of CD3+CD4+) and 42% IFN-γ (0.059% of
CD3+CD4+). Similar profiles were seen for the bystander antigens PPD and C. Alb. For PPD,
CD40L+CD4+ T cells comprised 0.041%, i.e ~30% of the TT response, with higher proportion of
cells producing IFN-γ (75%) than IL-2 (44%). Responses to C. Alb were lower but CD40L+CD4+
IL-2-producing T cells were clearly detectable (Fig 2A). Following a contraction at week 2, TT-
and PPD-specific responses remained detectable during the following weeks (Fig 2B).
Cumulative data from all five donors and complete kinetics are shown in S2 Fig. Although
kinetics varied among individuals, in all subjects the increase in TT-specific responses visible
one week after vaccination, was paralleled by an increase in PPD-specific responses. In subject
4, this was limited to a small increase in the number of IFN-γ-producing cells. Overall,
responses to C. Alb were generally weak, with an increase in CD4+CD40L+ cells visible at week
1 in 3/5 individuals (1, 4 and 5), and an increase in IL-2+ cells detected only in 1/5. As in subject
1 (Fig 2A and 2B), no production of IFN-γ in response to C. Alb could be seen in the remaining
subjects (S2 Fig).
In summary, vaccine-specific CD4+ T cell responses assessed by intracellular CD40L/cyto-
kine staining were paralleled by bystander T cell responses, confirming the observation from
IFN-γ ELISPOT. In each subject, the kinetics of the responses analyzed by the two methods
were largely similar (Fig 1 and S2 Fig).
Increase of CD4+ memory T cells following TT booster vaccination
Since a short exposure to antigen in vitro was required for detection of CD4+ T cells, it was nec-
essary to demonstrate the findings reflected real changes in blood precursor frequency rather
than being the consequence of enhanced reactivity leading to increased cytokine production
upon in vitro restimulation with antigen. If so, the observed changes in frequency of specific
populations of CD4+ memory T cells should be reflected in changes in the total CD4+ memory
T cells. Therefore, the question of whether bystander activation could lead to a rise in the total
Distinctiveness of Specific and Bystander Immunity
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Fig 2. Flow cytometric analysis of vaccine-specific and bystander CD4+ T cell responses to TT recall
vaccination detected by combined CD40L and cytokine intracellular staining. After a short term (6h) in
vitro culture in the absence (CTRL) or in the presence of either TT (10μg/ml), PPD (15μg/ml) or C.Alb (10μg/
ml), PBMNCwere first stained for surface CD3 and CD4, then permeabilized and stained intracellularly with
fluorescent antibodies specific for CD40L and the cytokines IL-2 and IFN-γ. (A) Data from one of the
individuals (subject 1) show the gating strategy (top three dot plots) and the detection of vaccine-specific (TT)
and bystander (PPD andC.Alb) CD4+ T cell responses before (pre-vaccination) and one week after (week 1)
a booster injection of TT. Percentages indicate the frequency of positive events within the CD3+CD4+
lymphocyte population. (B) Kinetics of vaccine-specific and bystander CD4+ T cell responses detected by
intracellular CD40L and cytokine staining in the same individual who received a booster vaccination (Wk 0)
with TT. Data indicate the frequency of positive cells within the CD3+CD4+ population, obtained from the
antigen-stimulated samples after subtracting the frequency of events in the control cultures. Responses were
considered positive if they met the criteria described in Materials and Methods. The dotted line shows the cut
off value of 0.01%.
doi:10.1371/journal.pone.0136717.g002
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number of CD4+ memory T cells was addressed. Immuno-phenotyping data from cells prior to
re-stimulation up to the week 8 time point are shown in Fig 3A. In all subjects, a transient
increase in the proportion of CD3+ cells was seen at week 1 over baseline (mean increase ±
SD = 6.9 ± 2%; P = 0.0015). In two cases (4 and 5), this was accompanied by an increase in the
percentage of CD4+ T cells and relative reduction in CD8+ T cells. In one subject (subject 2)
both CD4+ and CD8+ T cells increased with parallel reduction in CD4-CD8- T cells. In the
remaining subjects, no significant changes in the distribution of CD4+ and CD8+ T cells were
observed. Among CD4+ T cells, a consistent increase in the proportion of memory cells (mean
increase ± SD = 7.76 ± 3.65; P = 0.01) and a parallel reduction of naïve cells was evident at
week 1 in all subjects (mean decrease ± SD = 7.62 ± 3.45; P = 0.01). This was accounted for
mainly by a rise in central memory cells (Fig 3A). Interestingly, the smallest increase in mem-
ory cells with a relatively unchanged proportion of TCM cells was seen in subject 4, who had
showed the smallest increase of bystander CD4+ T cells as measured by intracellular CD40L/
cytokine staining (S2 Fig).
White blood cell (WBC) counts were available for 3 donors (subjects 1–3) (Table 1). Total
counts increased at week 1 in all subjects. In subjects 1 and 2, a rise in neutrophil counts con-
tributed mostly to this, whilst in subject 3, neutrophils, monocytes and lymphocytes all
Fig 3. Percentages (A) and absolute numbers (B) of relevant immune cell populations before (Wk 0) and up to 8 weeks after TT booster
vaccination. (A) Percentages of CD3+, CD3+CD4+, CD3+CD8+ and CD3+CD4-CD8- cells were determined on viable PBMNC prior to cell culture by flow
cytometry, gating on singlets first, and then on the lymphocyte population. A minimum of 100000 events were acquired. Combined staining for CD45RA and
CCR7 allowed discrimination of Naïve (CD45RA+ CCR7+), Memory (CD45RA-), central memory, TCM (CD45RA
- CCR7+) and effector memory, TEM
(CD45RA- CCR7-) CD3+CD4+ cells. (B) The absolute number of cells was calculated from the blood lymphocyte counts available for subjects 1, 2 and 3
(Table 1), and the phenotypic data.
doi:10.1371/journal.pone.0136717.g003
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increased. A rise in eosiniphils was also detected at week 1 in subject 1. Using the phenotypic
data, absolute numbers of cells were calculated, and are reported in Fig 3B. Changes in absolute
number of cells paralleled those seen in the percentage of cells, with augmented number of
CD3+ and CD3+CD4+ visible at week 1, and among the latter, a marked increase in memory
cells, particular of the central memory phenotype. Naïve cells remained stable in 2/3 individu-
als and increased only in subject 3, possibly as consequence of the increased number of lym-
phocytes (Fig 3B and Table 1).
In summary, increased numbers of white blood cells were detected one week after TT vacci-
nation. These comprised both innate and adaptive immune cells, and within the latter, CD3+
CD4+ memory T cells appeared to be particularly increased.
Vaccine-specific CD4+ T cells are mainly of effector memory type but
bystander T cells are mainly central memory
The distribution of the induced vaccine-specific and bystander CD4+ T cells into naïve (TN),
TCM, TEM and terminally differentiated (TTD) subsets was analyzed using CCR7 and CD45RA
expression [25]. Representative dot plots at week 1 time point are shown in Fig 4A. The TT
response is predominantly CD45RA negative (i.e. memory T cells) and most responding cells
are CCR7 negative, indicative of effector memory type. This is consistent across the total CD4+-
CD40L+ population (80.7% TEM) as well as the IL-2
+ and IFN-γ+ producing sub-populations,
the latter showing an even greater proportion (92.5%) of TEM cells.
The bystander response to PPD is also largely CD45RA negative; however, in contrast to the
vaccine-specific, the bystander CD4+CD40L+ T cells are mainly CCR7+ (71%), consistent with
central memory phenotype, with similar proportions of TCM found across IL-2
+ and IFN-γ+
Table 1. Total and differential white blood cell (WBC) counts (N x 109/L) before (Week 0) and at various
time points after TT booster vaccination in three healthy subjects. Full blood counts were carried out at
each study visit by the routine NHS laboratory.
Subject 1 Week 0 1 2 4 8
WBC (N x 109/L) 5.4 8.7 4.6 5.0 4.2
Neutrophils 2.5 5.4 2.5 2.6 2.2
Eosinophils 0.4 0.7 0.3 0.2 0.1
Basophils 0.1 0.0 0.0 0.0 0.0
Monocytes 0.4 0.5 0.5 0.4 0.3
Lymphocytes 2.0 2.1 1.3 1.7 1.6
Subject 2 Week 0 1 2 4 8
WBC (N x 109/L) 4.4 5.0 4.7 5.2 5.0
Neutrophils 2.2 2.6 2.3 2.8 2.6
Eosinophils 0.1 0.1 0.1 0.1 0.1
Basophils 0.0 0.0 0.0 0.0 0.0
Monocytes 0.5 0.5 0.6 0.6 0.4
Lymphocytes 1.7 1.8 1.7 1.7 1.9
Subject 3 Week 0 1 2 4 8
WBC (N x 109/L) 4.2 5.9 4.7 4.2 5.2
Neutrophils 2.1 2.6 2.6 1.9 2.3
Eosinophils 0.1 0.1 0.1 0.1 0.1
Basophils 0.0 0.0 0.0 0.0 0.0
Monocytes 0.3 0.6 0.6 0.3 0.6
Lymphocytes 1.6 2.5 1.4 2.0 2.2
doi:10.1371/journal.pone.0136717.t001
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Fig 4. Distribution of vaccine-specific (TT) and bystander (PPD,C.Alb) CD4+ CD40L+ and cytokine
positive T cells according to the expression of CD45RA and CCR7. After a short term (6h) in vitro culture
in the absence (control) or in the presence of either TT (10μg/ml), PPD (15μg/ml) or C.Alb (10μg/ml), antigen-
specific CD4+ T cells, identified by CD40L expression and cytokine (IL-2, IFN-γ) production (see Fig 2A),
were stained with CD45RA and CCR7 and the percentages of naïve (TN, CD45RA
+CCR7+), central memory
(TCM, CD45RA
-CCR7+), effector memory (TEM, CD45RA
-CCR7-) and terminally differentiated (TTD,
CD45RA+CCR7-) were calculated among the CD4+CD40L+, CD4+CD40L+IL-2+ and CD4+CD40L+IFN-γ+
cells. (A) Representative data from subject 1 showing the phenotype of vaccine-specific (TT) and bystander
(PPD,C.Alb) CD4+ T cells one week after booster vaccination with TT. The percentages of events in each
quadrant are indicated. Gates in dot plots were set using the appropriate isotype-matched controls.
Responding cells are CD45RA- memory type cells, but whilst the TT-specific are in their vast majority TEM,
bystander (PPD andC.Alb-specific) cells are mainly TCM. N.D. Responses not detected. (B) Cumulative data
(mean percentages) from five subjects, one week after TT vaccination showing the differential phenotype
between vaccine-specific and bystander responses. The numbers on the bars indicate the mean
percentages ± SD of TEM cells among the TT-specific, and of TCM cells among the PPD- andC.Alb-specific
Distinctiveness of Specific and Bystander Immunity
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sub-populations. The same distribution is also seen in cells responding to C. Alb (Fig 4A), with
TCM cells accounting for over 70% of the total population and almost 90% of IL-2-producing
cells. C.Alb-specific IFN-γ+ cells were not detected. Compiled data from all subjects at week 1
are reported as mean percentages in Fig 4B and S3B Fig, as well as individually in S3A Fig.
They are highly reproducible among the subjects and show the same pattern with a marked dif-
ference in the proportion of TEM cells (P<0.001), which constitute the majority of the vaccine-
specific population, and TCM cells (P<0.001) which are preponderant among the bystander
responding populations.
The kinetic of induction of TCM and TEM was then assessed and the ratios of TCM: TEM cells
over an 8 week period were calculated for both TT- and PPD-specific responses. Data from a
representative subject and cumulative data from all the individuals are reported in Fig 4C and
S4 Fig, respectively. For subjects 4 and 5, pre-vaccination T-cell responses against the two anti-
gens were detectable, albeit at the expected low frequency, allowing comparison between pre-
and post-vaccination phenotype.
Vaccination induced a shift within the TT-specific CD4+CD40L+ population, from either a
TCM-rich (subject 4; TCM/TEM = 1.45) or balanced (subject 5, TCM/TEM = 0.92) distribution
pre-vaccination to a post-vaccination response characterized by predominance of TEM cells in
both subjects (Fig 4C and S4 Fig). TT-specific IL-2 and IFN-γ-producing cells were not detect-
able in significant numbers in any subjects at baseline and always displayed a TEM phenotype
after vaccination (Fig 4C and S4 Fig). In contrast, PPD-specific responses, including cytokine-
producing cells, were of TCM type pre-vaccination and retained this phenotype throughout the
follow up period (Fig 4C and S4 Fig).
Vaccine-specific CD4+ memory T cells show reduced expression of IL-
7Rα and Bcl-2, but bystander cells maintain high levels of both
Expression of IL-7Rα (CD127) and the anti-apoptotic Bcl-2 tend to decrease in recently-gener-
ated effector CD4+ [26] and CD8+ [21] T cells. We therefore measured expression of CD127
and Bcl-2 on vaccine-specific and bystander CD4+CD40L+ T cells. Data over the 8 week follow
up period are shown for a representative subject in Fig 5A, and cumulative data for the remain-
ing subjects at week 1 are depicted in S5 Fig. Pre-vaccination TT-specific cells were
CD127HighBcl-2High. One week after vaccination, a significant proportion (median 78.1%,
range 50.0–90.1%; P< 0.001) showed reduced expression of both markers. The percentage of
CD127HighBcl-2High cells within the TT-specific CD4+CD40L+ population slowly increased in
the following weeks (Fig 5A), but remained significantly reduced relative to baseline until week
8 (Fig 5B).
In contrast, PPD-specific CD4+ CD40L+ T cells were also CD127HighBcl-2High at baseline,
but they maintained this phenotype one week after vaccination and at later time points (Fig 5A
and S5 Fig). The C.Alb specific response detected at week 1 was also characterized by cells uni-
formly high in CD127 and Bcl-2 (Fig 5A and S5 Fig).
Kinetic analysis (mean percentages ± SDEV) of CD127HighBcl-2High cells in all subjects is
displayed in Fig 5B and it shows the significant changes from baseline in the TT-specific
CD4+CD40L+ population and the remarkable stability of PPD-specific cell phenotype.
populations, respectively. C.Alb-specific CD40L+ cells were detected only in subjects 1, 4 and 5; C.Alb-
specific CD40L+IL-2+ cells were detected only in subject 1; C.Alb-specific CD40L+IFN-γ+ cells were not
detected in any subjects (N.D). (C) Kinetics of TCM to TEM ratio in vaccine-specific (TT) and bystander (PPD)
CD4+ CD40L+ T cells in subjects 4 before TT vaccination (Wk 0) and during follow up. Black asterisks
indicate time points where TT-specific responses were not detectable.
doi:10.1371/journal.pone.0136717.g004
Distinctiveness of Specific and Bystander Immunity
PLOS ONE | DOI:10.1371/journal.pone.0136717 September 2, 2015 11 / 19
Vaccine-specific but not bystander CD4+ memory T cells display high
levels of activation and proliferative activity
Activation status and in vivo proliferative activity of CD4+CD40L+ antigen-specific T cells were
investigated by analyzing expression of surface markers CD38 and HLA-DR, and intracellular
Ki-67, respectively (Fig 6). At week 1, a high percentage of vaccine-specific (TT) cells expressed
CD38 (median 84.9%, range 47.5–87.5%), and a proportion of these were HLA-DR+ (median
19.8%, range 3.5–24.8%). Importantly, the majority were also Ki-67+ (median 81.5%, range
38.7–87.0%) (Fig 6A). This indicates recent or on-going activation and proliferative activity.
Fig 5. Expression of CD127 (IL-7Rα) and Bcl-2 on vaccine-specific (TT) and bystander (PPD andC.Alb) CD4+CD40L+ T cells before (Wk 0) and at
various time points after TT booster vaccination. After a short term (6h) in vitro culture in the absence (control) or in the presence of either TT (10μg/ml),
PPD (15μg/ml) or C.Alb (10μg/ml), PBMNCwere first stained for surface CD3, CD4 and CD127, then permeabilized and stained intracellularly with
fluorescent antibodies specific for CD40L and Bcl-2. (A) Data from a representative subject showing how expression of CD127 and Bcl-2 is reduced following
TT booster vaccination on TT-specific, but not on bystander PPD-specific CD4+CD40L+ T cells. High expression of both markers is also found on C.Alb-
specific cells detected at week 1. The percentage of TT-specific cells with a CD127HighBcl-2High phenotype reaches its minimum one week after vaccination
and increases again in the following weeks. (B) Cumulative data on the proportion of CD4+CD40L+ TT-specific and PPD-specific T cells with a CD127HighBcl-
2High phenotype before (Wk 0) and after TT booster vaccination. Data indicate the mean ± standard deviation calculated from the individuals showing
detectable responses. Friedman paired analysis confirmed significant variance across time course for TT-specific population (P = 0.0031); individual P-
values given at each time point generated using paired T-test comparing to baseline. At week 0, responses to TT and PPD were detected in subjects 4 and 5;
at week 2, responses to PPD were detected in subjects 2 and 4; for all the remaining time points, responses to TT and PPD were detected in all subjects.
doi:10.1371/journal.pone.0136717.g005
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Fig 6. Analyis of activation (CD38, HLA-DR) and proliferation (Ki-67) markers on vaccine-specific (TT)
and bystander (PPD andC.Alb) CD4+CD40L+ T cells. After a short term (6h) in vitro culture in the absence
(control) or in the presence of either TT (10μg/ml), PPD (15μg/ml) or C.Alb (10μg/ml), PBMNC were first
stained for surface CD3, CD4, CD38 and HLA-DR, then permeabilized and stained intracellularly for CD40L
and Ki-67. (A) Data indicate the percentage of CD38, HLA-DR, Ki-67 single positive and CD38+Ki-67+ double
positive cells within the CD3+CD4+CD40L+ population in five healthy subjects one week after receiving a
booster vaccination with TT. Median values are indicated by a bar. Significance of the difference between
vaccine specific and bystander populations are indicated (NS—non-significant, * = P<0.01, ** = P<0.001),
as analysed using non-parametric Mann-Whitney U-test. (B) Representative dot plots from subject 5,
showing how at week 1 activated and proliferating (CD38+Ki-67+) cells are only found among the TT-specific
cells, but not among the bystander PPD- andC.Alb-specific cells. Percentages of positive cells in the
CD3+CD4+CD40L+ gated population are indicated in each quadrant. Gates in dot plots were set using the
appropriate isotype-matched controls. (C) Analysis of expression (%) of CD38, HLA-DR, Ki-67 single positive
and CD38+Ki-67+ double positive cells within the TT- and PPD-specific CD4+CD40L+ T cell populations
before (Wk 0) and at various time points after TT booster vaccination. Data indicate the mean ± standard
deviation calculated from the individuals showing detectable responses. P-values indicate the significant
changes in expression over baseline for all time points, calculated using paired T-test and confirmed using
Friedman’s test; non-significant changes are unlabeled. At week 0, responses to TT and PPD were detected
in subjects 4 and 5; at week 2, responses to PPD were detected in subjects 2 and 4; for all the remaining time
points, responses to TT and PPD were detected in all subjects.
doi:10.1371/journal.pone.0136717.g006
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Conversely, PPD- and C.Alb-specific CD4+CD40L+ T cells, despite showing some degree of
CD38 expression (medians 8.7 and 26.1%, ranges 4.6–31.6 and 19.7–35.3%, respectively),
remained HLA-DR negative and Ki-67 negative. Hence, whilst double positive (CD38+Ki-67+)
cells constituted the majority of TT-specific cells, they were virtually undetectable among the
bystander populations (Fig 6A and 6B).
Analysis of expression (mean % ± SDEV) of these markers in TT- and PPD-specific CD4+-
CD40L+ T cells pre- and post-vaccination is shown in Fig 6C. Clearly, the presence of activated
and proliferating cells (CD38+Ki-67+) among the vaccine-specific cells was transient. They
were absent at baseline, they increased significantly one week after vaccination (mean% TT
reactive cells expressing markers ± SD = 72.2 ± 22.3; P = 0.0024), and then rapidly declined,
with numbers at week 2 not significantly different to those at baseline (5.1 ± 4.0). This was
attributable to the rapid loss of Ki-67+ expression on cells (at week 2 only (8.8 ± 6.7) of TT-spe-
cific cells were still positive), whereas persistence of CD38+ expression on TT-specific cells at
week 2 was more varied across the cohort (60.3 ± 21.7. Range 31.0–79.0).
PPD-specific CD4+CD40L+ T cells, despite showing a small, non-significant increase in
CD38 expression following vaccination, always remained Ki-67 negative throughout the follow
up period.
Discussion
Dissecting the mechanisms responsible for the maintenance of T cell memory has major reper-
cussions on vaccine development. We have previously reported in a larger study [12], and con-
firmed here, that following TT recall vaccination, the Thmem immune response to TT, is
accompanied by an increase of vaccine unrelated Thmem cells. This phenomenon fits with the
view that there might be a “tick-over” mechanism acting globally on memory T cells so that
each time there is an infection, memory gets a stimulus, and this may contribute to memory
maintenance. Other circumstantial observations of parallel increase of heterologous immunity
following TT vaccination [27,28], and vice-versa, expansion of TT-specific CD4+ T cells during
an episode of common influenza virus infection [29], support this view.
To clarify the nature of the bystander cells and the mechanisms driving their increase in the
peripheral blood, we first addressed their phenotypic and functional features and we compared
them to those of vaccine-specific CD4+ memory T cells.
Analysis of the responses at the pre-vaccination baseline, revealed similarities between the TT-
specific and bystander (PPD-specific) CD4+ CD40L+ T cells: both were CD45RA-CCR7+ (TCM),
expressed high levels of CD127 and Bcl-2 and were not activated and non-proliferating. At the
peak of the response to vaccination (week 1), key differences emerged. The TT-specific CD4+ T
cells displayed the typical features of recently generated effector T cells. They were CCR7- (TEM),
mainly CD127LowBcl-2Low, and showed clear signs of activation (CD38+HLA-DR+) and prolifer-
ative activity (Ki-67+). This allows delineation of the response to vaccination within a naturally
fluctuating immune activity in human subjects. In contrast, both PPD- and C.Alb-specific CD4+
T cells maintained expression of CCR7 (TCM), CD127 and Bcl-2, and crucially, showed no evi-
dence of activation (HLA-DR- CD38Low) or proliferation (Ki-67-). These differences were consis-
tent in all the subjects.
To our knowledge, this is the first study to provide a detailed characterization of vaccine-
specific and bystander CD4+ memory T cells in response to protein vaccination and to identify
their distinct functional and phenotypic features. Cellerai et al. [26] studied phenotype and
function of vaccine-specific, but not bystander, CD4+ T cells before and after TT recall vaccina-
tion; they focused the analysis on cytokine-producing cells following 16h in vitro re-stimula-
tion with high antigen dose (100μg/ml TT). Here, conditions of minimal stimulation in vitro
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(6h, 10μg/ml TT) were designed to assess cell status in vivo by avoiding perturbation of T cell
phenotype and function; furthermore, CD40L expression analysis, allowed access to a wider
population of antigen-specific cells, including antigen-specific cells with non-immediate effec-
tor functions or with the potential to produce cytokines not commonly evaluated. Despite
these methodological differences, in both studies, the phenotypic characterization of TT-spe-
cific responses produced similar results.
With regard to bystander CD4+ memory T cells, the increased number detected one week
after vaccination, seems to reflect a real increase in precursor frequency, as evidenced by the
rise in the absolute number of circulating total CD4+ memory T cells (Fig 3), and of TCM cells
in particular. A similar apparent increase of non-proliferating CD4+ memory T cells specific
for TT was observed in healthy subjects undergoing primary vaccination with the yellow fever
vaccine [30], but no further phenotypic characterization of those cells was performed.
Expression of CCR7 on bystander cells is expected to confer the ability to re-circulate through
secondary lymphoid organs. Hence, these expanded cells may have originated from cells exposed
to the cytokine-rich microenvironment created in vaccine-draining lymph nodes by the second-
ary immune response to TT vaccination. Nonetheless, the lack of expression of activation and
proliferation markers observed at the peak of the vaccine-specific response (week 1) and after-
wards suggests that this is not the case. It appears more likely that the increase in circulating
bystander cells is the result of mobilization and migration into the blood stream of memory cells
resident in other compartments. Human CD4+ memory T cells residing in both lymphoid and
non-lymphoid (mucosal) tissues have been recently characterized [31]. They constitutively
express the T cell activation marker CD69, which is not expressed on their circulating counter-
part, and are CD127 (IL-7Rα) +. In the mouse, CD69 is required for the relocation of CD4+ T
cells from the blood to the bone marrow and their persistence there [32]. Human bone marrow
is enriched in polyfunctional CD4+ memory T cells that despite being CD69+ are in a resting
state, as indicated by lack of expression of Ki-67, and by cell cycle and transcriptome analysis
[33]. Furthermore, they express CD127 and appear protected from apoptosis [33]. We did not
investigate CD69 expression, as this marker would be promptly up regulated following the in
vitro re-stimulation with antigen required to identify antigen-specific CD4+ T cells in our sys-
tem. However, all the phenotypic feature of vaccine-stimulated bystander CD4+ memory T cells
appear to match those of the cells described above. In our study, the bystander Thmem cells
appeared non-activated and non-proliferating, but retained high expression of Bcl-2, indicative
of preserved survival potential. Furthermore, they displayed potential effector functions, as dem-
onstrated by the prompt production of cytokines after brief in vitro re-stimulation with cognate
antigen. Considering these similarities, it is therefore conceivable that the bystander cells we
detected after TT vaccination may derive from CD4+ memory T cells resident in tissues, possibly
the bone marrow, and mobilized following the recall vaccination. Interestingly, the increase of
non-vaccine specific Thmem cells we describe here, resembles that seen in the same vaccination
setting, of non-TT specific plasma cells. These appeared to be mobilized from survival niches in
the bone marrow by either competing newly formed TT-specific plasma blasts [34] or possibly
by the disruptive action of adjuvant (alum) stimulation [35]. To understand the role of alum in
relation to the increase of bystander CD4+ memory T cells, administration of alum as single
agent would be required, but it is unlikely to be ethically justifiable in humans.
In summary, it appears that following vaccination or infection, a pool of CD4+ memory T
cells are mobilized from depot tissues (e.g. the bone marrow) and enter the blood stream. This
perhaps is part of a response aimed at speeding up and raising defence against other opportu-
nistic pathogens. As the mobilized cells express CCR7, they could reach secondary lymphoid
organs, where the putative pathogen-derived antigens would in the meantime been transferred
and presented to them.
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The clear phenotypic distinction between vaccine-specific and vaccine-stimulated bystander
CD4+ memory T cells we provide here has not only biological but also important practical
implications for vaccinology. The increase of bystander CD4+ memory T cells following vacci-
nation poses problems to a correct evaluation of vaccine specific responses, because an increase
in vaccine-specific CD4+ memory T cells may result from their mobilization as a bystander
response to a different immunogen, rather than from specific proliferation to the vaccine. We
provide here the tools to integrate and validate results obtained by the quantitative analysis of
blood precursor frequency, to contribute to more accurate evaluation of the CD4+ T cell
response to vaccination in humans.
These findings reveal the dynamic nature of the T-cell arm of the human immune response
which underlies responses to environmental perturbations, measurement of immune responses
and disturbances in hematologic diseases.
Supporting Information
S1 Fig. Kinetics of vaccine-specific and bystander T cell responses to TT recall vaccination
measured by a 40h IFN-γ ELISPOT assay, using freshly isolated PBMNC. The assay was set
up within two hours of blood collection. Responses are reported as the mean number of
spots ± SD of triplicate antigen-stimulated cultures, after subtracting the correspondent nega-
tive (no antigen) control.
(TIF)
S2 Fig. Kinetics of vaccine-specific and bystander CD4+ T cell responses detected by intra-
cellular CD40L and cytokine staining in five healthy subjects, who received a booster vacci-
nation (Wk 0) with TT. After a short term (6h) in vitro culture in the absence (control) or in
the presence of either TT (10μg/ml), PPD (15μg/ml) or C.Alb (10μg/ml), PBMNC were first
stained for surface CD3 and CD4, then permeabilized and stained intracellularly with fluores-
cent antibodies specific for CD40L and the cytokines IL-2 and IFN-γ. Data indicate the fre-
quency of positive cells within the CD3+CD4+ population, obtained from the antigen-
stimulated samples after subtracting the frequency of events in the control (no antigen) cul-
tures. Responses were considered positive if they met the criteria described in Materials and
Methods. The dotted line in each graph shows the cut off value of 0.01%.
(TIF)
S3 Fig. Distribution of vaccine-specific (TT) and bystander (PPD, C.Alb) CD4+ CD40L+
and cytokine positive T cells according to the expression of CD45RA and CCR7. Five
healthy subjects received a booster vaccination of TT. PBMNC were cultured in vitro for 6h in
the absence (control) or in the presence of either TT (10μg/ml), PPD (15μg/ml) or C.Alb
(10μg/ml) and the distribution of naïve (TN, CD45RA
+CCR7+), central memory (TCM,
CD45RA-CCR7+), effector memory (TEM, CD45RA
-CCR7-) and terminally differentiated
(TTD, CD45RA
+CCR7-) was studied among the vaccine-specific and bystander CD4+CD40L+,
CD4+CD40L+IL-2+ and CD4+CD40L+IFN-γ+ cells, one week after vaccination. Responding
cells are CD45RA- memory type cells, but whilst the TT-specific are in their vast majority TEM,
bystander (PPD and C.Alb-specific) cells are mainly TCM. (A) Individual data. N.D. Responses
not detected. (B) Summary data for proportional representation of memory subtypes within
the antigen specific CD4+ T cell populations identified by either CD40L+, CD40L+IFNγ+ or
CD40L+IL-2+; proportional representation within vaccine-specific and bystander populations
compared using T-test with Holm-Sidak adjustment of P value to take account of multiple test-
ing. Significant differences highlighted () alongside given P-value.
(TIF)
Distinctiveness of Specific and Bystander Immunity
PLOS ONE | DOI:10.1371/journal.pone.0136717 September 2, 2015 16 / 19
S4 Fig. Kinetics of TCM to TEM ratio in vaccine-specific (TT) and bystander (PPD) CD4
+ T
cells in 5 healthy subjects before TT vaccination (Wk 0) and during follow up. PBMNC
were cultured for 6h in vitro in the absence (control) or in the presence of either TT (10μg/ml)
or PPD (15μg/ml) and the ratio between percentages of central memory (TCM,
CD45RA-CCR7+) and effector memory (TEM, CD45RA
-CCR7-) was calculated among the
total (CD40L+) and the cytokine (IL-2 and IFN-γ)-producing CD3+CD4+ T cells. Black aster-
isks and gray stars indicate time points where TT-specific and/or PPD-specific responses
respectively were not detectable.
(TIF)
S5 Fig. Analysis of CD127 and Bcl-2 expression on vaccine-specific (TT) and bystander
(PPD and C.Alb) CD4+CD40L+ T cells, one week after booster vaccination with TT. After a
short term (6h) in vitro culture in the absence (control) or in the presence of either TT (10μg/
ml), PPD (15μg/ml) or C.Alb (10μg/ml), PBMNC were first stained for surface CD3, CD4 and
CD127, then permeabilized and stained intracellularly with fluorescent antibodies specific for
CD40L and Bcl-2. Cumulative data showing the appearance of a population among the TT-
specific but not among PPD- and C.Alb-specific CD4+CD40L+ T cells, characterized by low
expression of CD127 and Bcl-2. N.D. Responses not detected.
(TIF)
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